Calcium flux in continuous venovenous haemodiafiltration with heparin and citrate anticoagulation

Critical Care and Resuscitation

Volumn 13, Issue 2, 2011, Pages 72-81

  Brain, Matthew ^a   Parkes, Scott ^a   Fowler, Peter ^a   Robertson, Iain ^b   Brown, Andrew ^a  

^a LAUNCESTON GENERAL HOSPITAL   (Australia)

^b UNIVERSITY OF TASMANIA   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; CALCIUM; CITRIC ACID; HEPARIN;

ADULT; AGED; ARTICLE; BLOOD; COMPARATIVE STUDY; CRITICAL ILLNESS; DRUG COMBINATION; FEMALE; FOLLOW UP; HEMODIAFILTRATION; HUMAN; HYPOCALCEMIA; INTENSIVE CARE UNIT; MALE; METABOLISM; METHODOLOGY; MIDDLE AGED; PROSPECTIVE STUDY; TREATMENT OUTCOME;

ADULT; AGED; ANTICOAGULANTS; CALCIUM; CITRIC ACID; CRITICAL ILLNESS; DRUG COMBINATIONS; FEMALE; FOLLOW-UP STUDIES; HEMODIAFILTRATION; HEPARIN; HUMANS; HYPOCALCEMIA; INTENSIVE CARE UNITS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 79960576822     PISSN: 14412772     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. Joannidis M, Oudemans-van Straaten HM. Clinical review: patency of the circuit in continuous renal replacement therapy. Crit Care 2007; 11: 218.
2. Oudemans-van Straaten HM, Bosman RJ, Koopmans M, et al. Citrate anticoagulation for continuous venovenous hemofiltration. Crit Care Med 2009; 37: 545-52.
3. Walser M. Ion Association. VI. Interactions between calcium, magnesium, inorganic phosphate, citrate and protein in normal human plasma. J Clin Invest 1961; 40: 723-30.
4. Moore EW. Ionized calcium in normal serum, ultrafiltrates, and whole blood determined by ion-exchange electrodes. J Clin Invest 1970; 49: 318-34.
5. Gambro Monitor Division. Presentation on Prismocitrate. Lundia, Sweden: Gambro, 2006.
6. Oudemans-van Straaten HM. Review and guidelines for regional anticoagulation with citrate in continuous hemofiltration. Neth J Crit Care 2004; 8: 146-56.
7. Meier-Kriesche HU, Finkel KW, Gitomer JJ, DuBose TD. Unexpected severe hypocalcemia during continuous venovenous hemodialysis with regional citrate anticoagulation. Am J Kidney Dis 1999; 33: e8.
8. Apsner R, Gruber D, Horl WH, Sunder-Plassmann G. Parathyroid hormone secretion during citrate anticoagulated hemodialysis in acutely ill maintenance hemodialysis patients. Anesth Analg 2004; 99: 1199-204.
9. Szamosfalvi B, Frinak S, Yee J. Automated regional citrate anticoagulation: technological barriers and possible solutions. Blood Purif 2010; 29: 204-9.
10. Gotch FA, Panlilio F, Sergeyeva O, et al. Effective diffusion volume flow rates (Qe) for urea, creatinine, and inorganic phosphorous (Qeu, Qecr, QeiP) during hemodialysis. Semin Dial 2003; 16: 474-6.
11. Hirsh J, Raschke R. Heparin and low-molecular-weight heparin: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126: 188S-203S.
12. Kozik-Jaromin J, Nier V, Heemann U, et al. Citrate pharmacokinetics and calcium levels during high-flux dialysis with regional citrate anticoagulation. Nephrol Dial Transplant 2009; 24: 2244-51.
13. Carlstedt F, Lind L, Wide L, et al. Serum levels of parathyroid hormone are related to the mortality and severity of illness in patients in the emergency department. Eur J Clin Invest 1997; 27: 977-81.
14. Whitfield L, Levy G. Permeability of human and rat red blood cells to citrate. Thromb Res 1981; 21: 681-4.
15. Gotch F, Kotanko P, Handelman G, Levin N. A kinetic model of calcium mass balance during dialysis therapy. Blood Purif 2007; 25: 139-49.
16. McLean FC, Hastings AB. The state of calcium in the fluids of the body. I. The conditions affecting the ionization of calcium. J Biol Chem 1935; 108: 285-321.
17. Sargent JA, Gotch FA. Principles and biophysics of dialysis. In: Jacobs C, Kjellstrand CM, Koch KM, editors. Replacement of renal function by dialysis. 4th ed. New York: Springer; 1996: 87-143.